Hugh M. Cole - 01 Aug 2022 Form 4 Insider Report for Jounce Therapeutics, Inc.

Role
Chief Operating Officer
Signature
/s/ Caroline Gammill, Attorney-in-fact
Issuer symbol
N/A
Transactions as of
01 Aug 2022
Net transactions value
$0
Form type
4
Filing time
03 Aug 2022, 20:29:55 UTC
Previous filing
21 Jun 2022
Next filing
11 Jan 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction JNCE Common Stock Award $0 +20,000 +19% $0.000000 126,716 01 Aug 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction JNCE Stock Option (Right to Buy) Award $0 +40,000 $0.000000 40,000 01 Aug 2022 Common Stock 40,000 $2.97 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option will vest quarterly in 16 equal installments following August 1, 2022.